Chronic pain is one of the most prevalent and complex medical conditions in the Western World. Some 20% of the population experiences chronic pain, resulting in large socio-economic impacts that include absenteeism, reduced productivity, and sufferers' high probability of leaving the workforce altogether.
Practitioners and health care providers, understandably, express great concern that 60% of their patients who are treated for chronic pain respond poorly to their prescriptive regimes. The toll on patients and the costs to society due to the problem of ineffective chronic pain drug treatment are enormous. Furthermore, many patients return to their clinics also experiencing the unwelcome side effects of the current treatment plans based on opioids, antidepressants, antiepileptics, benzodiazepines, and nonsteroidal anti- inflammatory drugs.QSPainRelief Prescribing Support Tool for Clinicians
QSPainRelief provides effective combinational treatment of chronic pain in individual patients by employing an innovative quantitative systems pharmacology (QSP) pain relief approach.
QSP is an interdisciplinary and holistic science, studying mechanisms of drug effects on the complex interactions between and within biological systems (the body) at the molecular, cellular, tissue, organ, organism, and population levels, using advanced mathematical modeling approaches. QSP is a powerful convergence of biological pathways and pharmacology, using mathematical models that facilitate discovery of new therapeutics and enable individualized medicine with existing drugs.
The Prescribing Support Tool assembles existing and new computational models that:
The Prescribing Support Tool is an integrated service for clinician use in predicting the optimal combination of existing pain drugs for individual patients.
Direct benefits and impacts for individual patients suffering from chronic pain include:
Direct benefits and impacts for clinicians in the treatment of patients with chronic pain:
QSPainRelief is a five-year, six-million-dollar pharmacological pain relief project. World-leading experts on chronic pain, pharmacology, pharmacogenomics, personalized medicine, systems biology, and in silico (computer) modeling (led by In Silico Biosciences, Inc.) joined forces in the QSPainRelief consortium to develop a validated computational model for identifying optimal personalized combination treatments of existing medications for individual patients.
The QSPainRelief consortium partners include academics, clinicians, companies, patients, and patient organizations which bring together the necessary and complementary expertise to:
In Silico Biosciences, Inc. (ISB) was founded in 2000 on the premise of modeling complex CNS disorders using advanced mathematical techniques. ISB is the only company in the world to combine the academic discipline of computational neurosciences with pharmacological and disease-related concepts with a laser-sharp focus on practical questions in pharmaceutical R&D. ISB has worked with 12 pharmaceutical companies (nine of them in the top-20) and three patient foundations. The platform of ISB prospectively, blindly, and correctly predicted three clinical trial outcomes with completely new targets in Alzheimer’s disease and schizophrenia. The company has published over 20 peer-reviewed papers and was able to secure international patents on the software platform, a first in biomedical modeling and simulation.
The company employs Quantitative Systems Pharmacology (QSP), involving a complex computer-based model of firing activity in neuronal circuits based on formalized domain expertise in neurosciences. Since 2000, In Silico Biosciences, Inc. has used QSP to support central nervous system research and development, making modeled results actionable with practical applications.
Beyond the State of the Art. The Prescribing Support Tool is beyond the state- of-the-art because of its innovative, highly integrative, and multi-disciplinary model to predict pain relief and side effects. It makes use of existing and newly generated data obtained from cellular, preclinical, and clinical studies, which is integrated by systems modeling approaches to understand the pathophysiology of pain in groups of patients responding well or poorly to particular combination therapies. The platform assembles existing and newly developed computational models into a highly sophisticated framework for predicting patient responses to new combination therapies that optimize analgesia and side effects for individual patients.
The Prescribing Support Tool is a user-friendly tool in the hands of clinicians for improved patient outcomes and greater patient satisfaction. The Tool provides clinicians an easy-to-use, calibrated, and validated computational platform to identify effective combination therapeutic drug interventions in individual chronic pain patients.